

REMARKS

Claims 1-43 are pending. Claims 3, 5, 9, 12, 13, 16-18, 21, 22, and 25-43 have been withdrawn as directed to a non-elected invention.

Responsive to the original Restriction/Election of Species Requirement, dated October 24, 2006, in the above-captioned application, Applicants elected, Groups I – XX (Claims 1-10, 12, 14, 15, 19, 20 and 23-27), and in particular an anti-OX40 antibody, with traverse, for further prosecution at this time.

With respect to the further species election required in the additional Restriction/Election of Species Requirement dated February 23, 2007, Applicants elect allogeneic and prostate cancer.

Applicants submit that the application supports method claims that are generically drawn to any additional cancer therapeutic agent and respectfully submit that a generic claim exemplified by Claim 1 is allowable.

CONCLUSION


In light of the above, Applicants submit that this application is now in condition for allowance and therefore request favorable consideration. If any issues remain which the Examiner feels may be best resolved through a personal or telephonic interview, the Examiner is respectfully requested to contact Applicants' counsel, Linda R. Judge at (415) 836-2586.

No fees beyond are believed to be due in connection with this Amendment. However, the Director is authorized to charge any additional fees that may required, or credit any overpayment, to DLA Piper US LLP Deposit Account No. 07-1896 (Order No. 3802-090-27 CIP (306229-114)).

Respectfully submitted,

Date: 4/12/07

Customer No. 29585
DLA Piper US LLP
Telephone: 415-836-2500
Facsimile: 415-836-2501


Linda R. Judge
Reg. No. 42,702